Deep vein thrombosis prophylaxis

Chest

Volumn 136, Issue 6, 2009, Pages 1699-1700

  Weber, Kristy L ^a,b   Zuckerman, Joseph D ^c,d   Watters III, William C ^e,f   Turkelson, Charles M ^g  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b American Academy of Orthopaedic Surgeons   (United States)

^c NYU HOSPITAL FOR JOINT DISEASES   (United States)

^d American Academy of Orthopaedic Surgeons   (United States)

^e Memorial Bone and Joint Clinic   (United States)

^f American Academy of Orthopaedic Surgeons   (United States)

^g American Academy of Orthopaedic Surgeons   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEEDING; CLINICAL FEATURE; CLINICAL PRACTICE; DEEP VEIN THROMBOSIS; HUMAN; LETTER; LUNG EMBOLISM; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR;

EID: 73149109076     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-1218     Document Type: Letter

References (10)

1. Eikelboom JW, Karthikeyan G, Fagel N, et al. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest 2009; 135:513-520
2. Lassere MN, Johnson KR, Boers M, et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol 2007; 34:607-615
3. Bucher HC, Guyatt GH, Cook DJ, et al. Users' guides to the medical literature: XIX. Applying clinical trials results: A. How to use an article measuring the effect of an intervention on surrogate end points. JAMA 1999; 282:771-778
4. Baker SG, Kramer SB. A perfect correlate does not a surrogate make. BMC Med Res Methodol 2003; 3:16-20
5. Gail MH, Pfeiffer R, Houwelingen HC, et al. On meta-analytic assessment of surrogate outcomes. Biostatistics 2001; 3:231-246
6. Prentiss RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-440
7. Kassai B, Shah NR, Leizorovicza A, et al. The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests. J Clin Epidemiol 2005; 58:1042-1051
8. Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 2006; 105:1114-1118
9. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125:605-613
10. American Academy of Orthopaedic Surgeons. Guideline on the prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. Available at: http://www.aaos.org/research/guidelines/PEguide.asp. Accessed October 28, 2009